ANRS 0288s - VIROPREG
Pregnancy and viral infections: impact on pregnant women and children. French prospective cohort study.
Last updated on 20 May 2026
Main points
- The purpose of the ANRS Viropreg cohort is to study chronic viral infections and (re)emerging viral infections and the risks associated with exposure to these viruses in pregnant women and their foetuses.
- Initially, the cohort will focus on HIV-1/HIV-2 infection, chronic viral hepatitis and arboviruses in order to assess the risk of mother-to-foetus transmission and the impact of infection on both the course and outcome of pregnancy and on the short- and long-term health of the unborn child. Other more specific issues related to the viral infection in question will also be studied, such as difficulties in accessing care or remaining in the healthcare system, and the impact of social and individual characteristics on the occurrence of viral infections and their consequences.
- Subsequently, depending on the various viral emergences/re-emergences whose impact (of the infection itself and/or its treatment) on (i) the health of the pregnant woman, (ii) the course of pregnancy, and (iii) the health of the unborn child, are still poorly or inadequately characterised (dengue, chikungunya, HTLV-1, etc.), the protocol will be extended, by way of an amendment, to cover other (re)emerging viral infections.
Type of study
Prospective, multicentre, national cohort study with hospital recruitment and different modules corresponding to the viral infections studied.
Study goals
HIV-1/HIV-2 Cohort
Assess the impact of exposure to HIV–1/HIV–2 and antiretroviral (ARV) treatment received during pregnancy and the neonatal period on gross and fine motor skills and socio–emotional development in the medium term (at age 4) of children born to mothers living with HIV–1/HIV–2.
Hepatitis B Module Cohort
Estimate the rate of mother-to-child transmission of HBV at 9 months of age in children born to mothers infected with HBV.
Hepatitis C Module Cohort
Estimate the rate of mother-to-child transmission of HCV between 18 and 24 months of age in children born to mothers infected with HCV.
Arbovirus Module Cohort
Estimate, by arbovirus type, the prevalence of adverse pregnancy outcomes in pregnant women with biologically confirmed symptomatic arbovirus infection.
Co-investigators
Pr Jeanne Sibiude and Pr Pierre Frange
Pathologies
Emerging and re-emerging viroses
Number of participants
2 580 mother-child couples
Duration
– Start date: 19 May 2026
– Estimated end date of study: 8 March 2036
Promotion
Inserm – ANRS MIE
Teams
– Methodology and Management Centre at Bichat Claude Bernard Hospital, head: Pr Cédric Laouenan
– Pharmacology Laboratory at Bichat-Claude Bernard Hospital, head: Dr Gilles Peytavin
– Virology Laboratory at Pitié Salpêtrière Hospital, head: Dr Ève TODESCO
